The Russian national Parliament (State Duma) plans to approve a bill that will ease imports of active pharmaceutical ingredients (APIs) to the country, according to press-service of the Russian Duma, reports The Pharma Letter’s local correspondent.
Under the current Russian legislation, the country’s state register of drugs usually contains information about an active substance of the drug, instead of a finished product. Therefore drug imports to Russia are usually associated with the need to conduct several examinations of these products. The first of them involves checking the quality of the substance in the composition of the drug, while the second one checking an actual presence of an active substance.
A spokesman of the Russian State Duma said the new state initiative could be beneficial for domestic drugmakers, as it will provide significant savings for them, both in terms of finance and timing. According to him, the existence of such checks significantly slows down and increases the cost of import substitution for the Russian pharmaceutical industry. This leads to discrimination against domestic producers, and significantly increases the time and cost of finished products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze